Systemic lupus erythematosus (SLE) patients have a higher risk of acute myocardial infarction (AMI) compared to the general population. However, the underlying common mechanism of this association is not fully understood. This study aims to investigate the molecular mechanism of this complication.
Methods
Gene expression profiles of SLE (GSE50772) and AMI (GSE66360) were obtained from the Gene Expression Omnibus (GEO) database. Common differentially expressed genes (DEGs) in SLE and AMI were identified, and functional annotation, protein-protein interaction (PPI) network analysis, module construction, and hub gene identification were performed. Additionally, transcription factor (TF)-gene regulatory network and TF-miRNA regulatory network were constructed for the hub genes.
Results
70 common DEGs (7 downregulated genes and 63 upregulated genes) were identified and were mostly enriched in signaling pathways such as the IL-17 signaling pathway, TNF signaling pathway, lipid metabolism, and atherosclerosis. Using cytoHubba, 12 significant hub genes were identified, including IL1B, TNF, FOS, CXCL8, JUN, PTGS2, FN1, EGR1, CXCL1, DUSP1, MMP9, and ZFP36.
Conclusions
This study reveals a common pathogenesis of SLE and AMI and provides new perspectives for further mechanism research. The identified common pathways and hub genes may have important clinical implications for the prevention and treatment of AMI in SLE patients.
FrostegårdJ. Systemic lupus erythematosus and cardiovascular disease. J Intern Med2023; 293: 48–62. DOI: 10.1111/joim.13557 (Accessed on 20 August 2022).
2.
CrocaSRahmanA. Atherosclerosis in systemic lupus erythematosus. Best Pract Res Clin Rheumatol2017; 31: 364–372. DOI: 10.1016/j.berh.2017.09.012 (Accessed on 12 December 2017).
3.
ChandrashekharYAlexanderTMullasariA, et al.Resource and infrastructure-appropriate management of st-segment elevation myocardial infarction in low- and middle-income countries. Circulation2020; 141: 2004–2025. DOI: 10.1161/circulationaha.119.041297 (Accessed on 17 June 2020).
4.
ReedGWRossiJECannonCP. Acute myocardial infarction. Lancet2017; 389: 197–210. DOI: 10.1016/S0140-6736(16)30677-8 (Accessed on 10 August 2016).
5.
TornvallPGöranssonAEkmanJ, et al.myocardial infarction in systemic lupus erythematosus: incidence and coronary angiography findings. Angiology2021; 72: 459–464. DOI: 10.1177/0003319720985337 (Accessed on 09 January 2021).
6.
KeSRLiuCWWuYW, et al.Systemic lupus erythematosus is associated with poor outcome after acute myocardial infarction. Nutrition, metabolism, and cardiovascular diseases: Nutr Metabol Cardiovasc Dis2019; 29: 1400–1407. DOI: 10.1016/j.numecd.2019.08.006 (Accessed on 28 October 2019).
7.
BarrettTTroupDWilhiteS, et al.NCBI GEO: archive for functional genomics data sets--10 years on. Nucleic Acids Res2011; 39: D1005–D1010. DOI: 10.1093/nar/gkq1184.
8.
KennedyWPMaciucaRWolslegelK, et al.Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus science & medicine2015; 2: e000080. DOI: 10.1136/lupus-2014-000080 (Accessed on 11 April 2015).
9.
MuseEKramerEWangH, et al.A whole blood molecular signature for acute myocardial infarction. Sci Rep2017; 7: 12268. DOI: 10.1038/s41598-017-12166-0.
10.
Warde-FarleyDDonaldsonSComesO, et al.The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res2010; 38: W214–W220. DOI: 10.1093/nar/gkq537.
11.
SafiriSKaramzadNSinghK, et al.Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990-2019. Eur J Prev Cardiol2022; 29: 420–431. DOI: 10.1093/eurjpc/zwab213 (Accessed on 19 December 2021).
12.
ReesFDohertyMGraingeM, et al.Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012. Rheumatology2016; 55: 854–860. DOI: 10.1093/rheumatology/kev424.
13.
FischerLSchliengerRMatterC, et al.Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol2004; 93: 198–200. DOI: 10.1016/j.amjcard.2003.09.037.
14.
Fernández-NebroARúa-FigueroaÍLópez-LongoF, et al.Cardiovascular events in systemic lupus erythematosus: a nationwide study in spain from the RELESSER registry. Medicine (Baltim)2015; 94: e1183. DOI: 10.1097/md.0000000000001183.
15.
Rafael-VidalCPérezNAltabásI, et al.Blocking IL-17: a promising strategy in the treatment of systemic rheumatic diseases. Int J Mol Sci2020; 21(19): 7100. DOI: 10.3390/ijms21197100.
16.
CostaRAntunesPSalvadorP, et al.Secukinumab on Refractory Lupus Nephritis. Cureus2021; 13: e17198. DOI: 10.7759/cureus.17198.
17.
Mora-RuízMBlanco-FavelaFChávez RuedaA, et al.Role of interleukin-17 in acute myocardial infarction. Mol Immunol2019; 107: 71–78. DOI: 10.1016/j.molimm.2019.01.008.
18.
TseliosKKoumarasCGladmanD, et al.Dyslipidemia in systemic lupus erythematosus: just another comorbidity?Semin Arthritis Rheum2016; 45: 604–610. DOI: 10.1016/j.semarthrit.2015.10.010.
19.
WangYYuHHeJ. Role of dyslipidemia in accelerating inflammation, autoimmunity, and atherosclerosis in systemic lupus erythematosus and other autoimmune diseases. Discov Med2020; 30: 49–56.
20.
ThygesenKAlpertJSJaffeAS, et al.Fourth universal definition of myocardial infarction (2018). Circulation2018; 138: e618–e651. DOI: 10.1161/CIR.0000000000000617 (Accessed on 21 December 2018).
21.
SamuelssonIParodisIGunnarssonI, et al.Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control study. Lupus science & medicine2021; 8(1): e000515. DOI: 10.1136/lupus-2021-000515 (Accessed on 23 July 2021).
22.
FieldsJGüntherSSundbergE. Structural basis of IL-1 family cytokine signaling. Front Immunol2019; 10: 1412. DOI: 10.3389/fimmu.2019.01412.
23.
WuYCaiBZhangJ, et al.βIL-1 and IL-6 are highly expressed in RF+IgE+ systemic lupus erythematous subtype. Journal of immunology research2017; 2017: 5096741. DOI: 10.1155/2017/5096741.
24.
UmareVPradhanVNadkarM, et al.Effect of proinflammatory cytokines (IL-6, TNF-α, and IL-1β) on clinical manifestations in Indian SLE patients. Mediat Inflamm2014; 2014: 385297. DOI: 10.1155/2014/385297.
25.
SilvainJKerneisMZeitouniM, et al.Interleukin-1β and risk of premature death in patients with myocardial infarction. J Am Coll Cardiol2020; 76: 1763–1773. DOI: 10.1016/j.jacc.2020.08.026.
26.
EverettBMacFadyenJThurenT, et al.Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial. J Am Coll Cardiol2020; 76: 1660–1670. DOI: 10.1016/j.jacc.2020.08.011.
27.
JangDLeeAShinH, et al.The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci2021; 22(5): 2719. DOI: 10.3390/ijms22052719.
28.
LiDZhaoLLiuM, et al.Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction. Am Heart J1999; 137: 1145–1152. DOI: 10.1016/s0002-8703(99)70375-3.
29.
BejjaniFEvannoEZibaraK, et al.The AP-1 transcriptional complex: local switch or remote command?Biochim Biophys Acta Rev Cancer2019; 1872: 11–23. DOI: 10.1016/j.bbcan.2019.04.003.
30.
LuoSZhangHXieY, et al.Decreased SUV39H1 at the promoter region leads to increased CREMα and accelerates autoimmune response in CD4 T cells from patients with systemic lupus erythematosus. Clin Epigenet2022; 14: 181. DOI: 10.1186/s13148-022-01411-7.
31.
KyttarisVJuangYTenbrockK, et al.Cyclic adenosine 5’-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J Immunol2004; 173: 3557–3563. DOI: 10.4049/jimmunol.173.5.3557.
32.
ZhangSZhangMGoldsteinS, et al.The effect of c-fos on acute myocardial infarction and the significance of metoprolol intervention in a rat model. Cell Biochem Biophys2013; 65: 249–255. DOI: 10.1007/s12013-012-9428-0.
33.
FerrerMBusquets-CortésCCapóX, et al.Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases. Curr Med Chem2019; 26: 3225–3241. DOI: 10.2174/0929867325666180514112124.
34.
XuLZhangLYiY, et al.Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med2004; 10: 411–415. DOI: 10.1038/nm1005.
35.
SaitoTRodgerIShennibH, et al.Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor. Can J Physiol Pharmacol2003; 81: 114–119. DOI: 10.1139/y03-023.
36.
PattenJWangK. Fibronectin in development and wound healing. Adv Drug Deliv Rev2021; 170: 353–368. DOI: 10.1016/j.addr.2020.09.005.
37.
CarsonsS. High levels of fibronectin fragments in the plasma of a patient with active systemic lupus erythematosus. J Rheumatol1987; 14: 1052–1054.
38.
OremCCelikSOremA, et al.Increased plasma fibronectin levels in patients with acute myocardial infarction complicated with left ventricular thrombus. Thromb Res2002; 105: 37–41. DOI: 10.1016/s0049-3848(01)00414-5.
39.
Gómez-MartínDDíaz-ZamudioMGalindo-CamposM, et al.Early growth response transcription factors and the modulation of immune response: implications towards autoimmunity. Autoimmun Rev2010; 9: 454–458. DOI: 10.1016/j.autrev.2009.12.006.
40.
ScharerCBlalockEMiT, et al.Epigenetic programming underpins B cell dysfunction in human SLE. Nat Immunol2019; 20: 1071–1082. DOI: 10.1038/s41590-019-0419-9.
41.
PanJAlimujiangMChenQ, et al.Exosomes derived from miR-146a-modified adipose-derived stem cells attenuate acute myocardial infarction-induced myocardial damage via downregulation of early growth response factor 1. J Cell Biochem2019; 120: 4433–4443. DOI: 10.1002/jcb.27731.
42.
WangJZhouJKhoD, et al.Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy. Autophagy2016; 12: 1791–1803. DOI: 10.1080/15548627.2016.1203483.
43.
ChuangHTanT. MAP4K family kinases and DUSP family phosphatases in T-Cell signaling and systemic lupus erythematosus. Cells2019; 8(11): 1433. DOI: 10.3390/cells8111433.
44.
ZhangYReynoldsJChangS, et al.MKP-1 is necessary for T cell activation and function. J Biol Chem2009; 284: 30815–30824. DOI: 10.1074/jbc.M109.052472.
45.
ShanJJinHXuY. T cell metabolism: a new perspective on Th17/treg cell imbalance in systemic lupus erythematosus. Front Immunol2020; 11: 1027. DOI: 10.3389/fimmu.2020.01027.
46.
JinQLiRHuN, et al.DUSP1 alleviates cardiac ischemia/reperfusion injury by suppressing the Mff-required mitochondrial fission and Bnip3-related mitophagy via the JNK pathways. Redox Biol2018; 14: 576–587. DOI: 10.1016/j.redox.2017.11.004.
47.
Ghafouri-FardSShahirMTaheriM, et al.A review on the role of chemokines in the pathogenesis of systemic lupus erythematosus. Cytokine2021; 146: 155640. DOI: 10.1016/j.cyto.2021.155640 (Accessed on 13 July 2021).
48.
MaoYZhaoCLiuL, et al.Increased circulating interleukin-8 levels in systemic lupus erythematosus patients: a meta-analysis. Biomarkers Med2018; 12: 1291–1302. DOI: 10.2217/bmm-2018-0217.
49.
SheteligCLimalanathanSHoffmannP, et al.Association of IL-8 With infarct size and clinical outcomes in patients with STEMI. J Am Coll Cardiol2018; 72: 187–198. DOI: 10.1016/j.jacc.2018.04.053.
50.
XuSLiY. Fisetin inhibits pristine-induced systemic lupus erythematosus in a murine model through CXCLs regulation. Int J Mol Med2018; 42: 3220–3230. DOI: 10.3892/ijmm.2018.3903.
51.
PordelSSajedi KhanianMKarimiM, et al.Plasma CXCL1 levels and TRAF3IP2 variants in patients with myocardial infarction. J Clin Lab Anal2018; 32: e22402. DOI: 10.1002/jcla.22402.
52.
VandoorenJVan den SteenPOpdenakkerG. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol2013; 48: 222–272. DOI: 10.3109/10409238.2013.770819.
53.
MaoYWangSZhaoC, et al.Circulating matrix metalloproteinase-9 levels in patients with systemic lupus erythematosus: a meta-analysis. Curr Pharmaceut Des2018; 24: 1780–1787. DOI: 10.2174/1381612824666180607123431.
54.
ZhangYLinPJiangH, et al.Extensive serum biomarker analysis in patients with ST segment elevation myocardial infarction (STEMI). Cytokine2015; 76: 356–362. DOI: 10.1016/j.cyto.2015.06.015.
55.
FengBLiH. Genetic polymorphism of matrix metalloproteinase-9 and susceptibility to myocardial infarction: a meta-analysis. Dis Markers2022; 2022: 5507153. DOI: 10.1155/2022/5507153.
56.
BlackshearP. Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem Soc Trans2002; 30: 945–952. DOI: 10.1042/bst0300945.
57.
WuFHuangWTanQ, et al.ZFP36L2 regulates myocardial ischemia/reperfusion injury and attenuates mitochondrial fusion and fission by LncRNA PVT1. Cell Death Dis2021; 12: 614. DOI: 10.1038/s41419-021-03876-5.
58.
HobertO. Gene regulation by transcription factors and microRNAs. Science2008; 319: 1785–1786. DOI: 10.1126/science.1151651.
59.
OeckinghausAGhoshS. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harbor Perspect Biol2009; 1: a000034. DOI: 10.1101/cshperspect.a000034.
60.
DongPLiuKHanH. The role of NF-κB in myocardial ischemia/reperfusion injury. Curr Protein Pept Sci2022; 23: 535–547. DOI: 10.2174/1389203723666220817085941.
61.
JiangJZhouZLiuY, et al.Role of Sp1 in atherosclerosis. Mol Biol Rep2022; 49: 9893–9902. DOI: 10.1007/s11033-022-07516-9.
62.
JuangYRauenTWangY, et al.Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus. J Biol Chem2011; 286: 1795–1801. DOI: 10.1074/jbc.M110.166785.
63.
LongGWangFDuanQ, et al.Circulating miR-30a, miR-195 and let-7b associated with acute myocardial infarction. PLoS One2012; 7: e50926. DOI: 10.1371/journal.pone.0050926 (Accessed on 14 December 2012).
64.
BlancoLPWangXCarlucciPM, et al.RNA externalized by neutrophil extracellular traps promotes inflammatory pathways in endothelial cells. Arthritis Rheumatol2021; 73: 2282–2292. DOI: 10.1002/art.41796 (Accessed on 14 May 2021).
65.
AdaySHazan-HalevyIChamorro-JorganesA, et al.Bioinspired artificial exosomes based on lipid nanoparticles carrying let-7b-5p promote angiogenesis in vitro and in vivo. Mol Ther2021; 29: 2239–2252. DOI: 10.1016/j.ymthe.2021.03.015 (Accessed on 22 March 2021).
66.
ZhangJQiuWMaJ, et al.miR-27a-5p attenuates hypoxia-induced rat cardiomyocyte injury by inhibiting Atg7. Int J Mol Sci2019; 20(10): 2418. DOI: 10.3390/ijms20102418 (Accessed on 19 May 2019).
67.
ZhangHHuangXYeL, et al.B cell-related circulating micrornas with the potential value of biomarkers in the differential diagnosis, and distinguishment between the disease activity and lupus nephritis for systemic lupus erythematosus. Front Immunol2018; 9: 1473. DOI: 10.3389/fimmu.2018.01473 (Accessed on 17 July 2018).
68.
DongSChengYYangJ, et al.MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem2009; 284: 29514–29525. DOI: 10.1074/jbc.M109.027896 (Accessed on 27 August 2009).
69.
ZhangYLiuYJLiuT, et al.Plasma microRNA-21 is a potential diagnostic biomarker of acute myocardial infarction. Eur Rev Med Pharmacol Sci2016; 20: 323–329 (Accessed on 16 February 2016).
70.
LiWLiuSChenY, et al.Circulating exosomal microRNAs as biomarkers of systemic lupus erythematosus. Clinics2020; 75: e1528. DOI: 10.6061/clinics/2020/e1528 (Accessed on 03 September 2020).
71.
LiMTangXLiuX, et al.Targeted miR-21 loaded liposomes for acute myocardial infarction. J Mater Chem B2020; 8: 10384–10391. DOI: 10.1039/d0tb01821j (Accessed on 29 October 2020).
